Miguel Bajouco

Miguel Bajouco

Auto-generated profile, based on publicly available information

Miguel Bajouco

Centro de Responsabilidade Integrado de Psiquiatria e Saúde Mental, Unidade Local de Saúde de Coimbra, Coimbra, Portugal; Centro de Imagem Biomédica e Investigação Translacional (CIBIT), Universidade de Coimbra, Coimbra, Portugal; Instituto de Psicologia Médica, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2016 in International Journal of Clinical Neurosciences and Mental Health
Verified
Journal Article
Closed access
NMNuno Madeira
Nuno Madeira
SCSalomé Caldeira
Salomé Caldeira
MBMiguel Bajouco
Miguel Bajouco
APAna Telma Pereira
Ana Telma Pereira
MMMaria João Martins
Maria João Martins
AMAntónio Macedo
António Macedo

1 March 2019 in Psychiatry Research
Verified
Journal Article
Closed access
MMMaria João R.V. Martins
Maria João R.V. Martins
APAna M Pinto
Ana M Pinto
PCPaula Castilho
Paula Castilho
AMAntónio Macedo
António Macedo
APAna Telma Pereira
Ana Telma Pereira
CBCélia Barreto-Carvalho
Célia Barreto-Carvalho

19 July 2017 in Psychosis
Verified
Journal Article
Closed access
MMMaria João Martins
Maria João Martins
PCPaula Castilho
Paula Castilho
CCCélia Barreto Carvalho
Célia Barreto Carvalho
APAna Telma Pereira
Ana Telma Pereira
DCDiana Carvalho
Diana Carvalho
AMAntónio Macedo
António Macedo
Fears of Compassion (FOC) relate to experiencing defensive emotions and avoidance reactions when receiving and giving compassion. Three different flows have been identified: giving compassion to others, receiving compassion, and self-compassion. This study sought to explore: FOC within a sample of patients with psychosis; the associations between FOC and paranoia; and the mediator role of FOC in the relationship between paranoid conviction and distress. Seventy-two patients with psychosis (74% diagnosed with schizophrenia), mostly male (85%), with a mean age of 33.46 (SD = 9.43), were recruited and assessed with measures of paranoia (conviction and distress) and FOC. Participants presented significantly higher levels of FOC than non-clinical samples and lower levels than depressed patients. Different flows of FOC were associated with each other and with paranoia-related measures. A mediation effect of FOC from others and fears of self-compassion was found. Results support the relevance of including FOC in formulation and treatment protocols for psychosis.

22 November 2021 in Early Intervention in Psychiatry
Verified
Journal Article
Closed access
PDF file
SFSofia Ramos Ferreira
Sofia Ramos Ferreira
DMDiana Moura
Diana Moura
POPedro Oliveira
Pedro Oliveira
VSVítor Santos
Vítor Santos
MBMiguel Bajouco
Miguel Bajouco
NMNuno Madeira
Nuno Madeira

1 July 2022 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
MBMiguel Bajouco
Miguel Bajouco
DMDavid Mota
David Mota
Cariprazine is an atypical antipsychotic that has D2 and D3 partial agonism properties in addition to the usual 5-HT2A receptor antagonist action of second-generation antipsychotics. It has a distinctly higher affinity for D3 receptors, which is 10-fold higher than for D2 receptors. Cariprazine is also a 5-HT1A partial agonist, with a potential antidepressant effect. Cariprazine has been approved for treatment of both positive and negative symptoms of schizophrenia and for treatment of bipolar disorder. It could potentially be used in depression as an add-on treatment. There are few data reporting effectiveness of cariprazine in the broader spectrum of psychosis. In this paper, the authors report three cases where cariprazine was used in the treatment of psychotic conditions other than schizophrenia, namely a first episode psychosis, a case of delusional disorder, and a case of a patient with borderline personality disorder and psychotic symptoms. The authors suggest that cariprazine may be effective in the treatment of psychosis in a broader sense and should be considered a first-line treatment option.

15 November 2017 in International Journal of Clinical Neurosciences and Mental Health
Verified
Journal Article
Closed access
MBMiguel Bajouco
Miguel Bajouco
DMDavid Mota
David Mota
MCManuel Coroa
Manuel Coroa
SCSalomé Caldeira
Salomé Caldeira
VSVitor Santos
Vitor Santos
NMNuno Madeira
Nuno Madeira